Key Insights
- The projected fair value for Sichuan Kelun Pharmaceutical is CN¥61.60 based on 2 Stage Free Cash Flow to Equity
- Current share price of CN¥31.08 suggests Sichuan Kelun Pharmaceutical is potentially 50% undervalued
- The CN¥42.04 analyst price target for 2422 is 32% less than our estimate of fair value
Today we will run through one way of estimating the intrinsic value of Sichuan Kelun Pharmaceutical Co., Ltd. (SZSE:002422) by taking the forecast future cash flows of the company and discounting them back to today's value. The Discounted Cash Flow (DCF) model is the tool we will apply to do this. Before you think you won't be able to understand it, just read on! It's actually much less complex than you'd imagine.
Companies can be valued in a lot of ways, so we would point out that a DCF is not perfect for every situation. Anyone interested in learning a bit more about intrinsic value should have a read of the Simply Wall St analysis model.
Is Sichuan Kelun Pharmaceutical Fairly Valued?
We're using the 2-stage growth model, which simply means we take in account two stages of company's growth. In the initial period the company may have a higher growth rate and the second stage is usually assumed to have a stable growth rate. To begin with, we have to get estimates of the next ten years of cash flows. Seeing as no analyst estimates of free cash flow are available to us, we have extrapolate the previous free cash flow (FCF) from the company's last reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.
Generally we assume that a dollar today is more valuable than a dollar in the future, and so the sum of these future cash flows is then discounted to today's value:
10-year free cash flow (FCF) forecast
2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | |
Levered FCF (CN¥, Millions) | CN¥3.99b | CN¥4.25b | CN¥4.49b | CN¥4.70b | CN¥4.89b | CN¥5.08b | CN¥5.26b | CN¥5.43b | CN¥5.61b | CN¥5.78b |
Growth Rate Estimate Source | Est @ 8.23% | Est @ 6.63% | Est @ 5.51% | Est @ 4.73% | Est @ 4.18% | Est @ 3.80% | Est @ 3.53% | Est @ 3.34% | Est @ 3.21% | Est @ 3.12% |
Present Value (CN¥, Millions) Discounted @ 7.4% | CN¥3.7k | CN¥3.7k | CN¥3.6k | CN¥3.5k | CN¥3.4k | CN¥3.3k | CN¥3.2k | CN¥3.1k | CN¥2.9k | CN¥2.8k |
("Est" = FCF growth rate estimated by Simply Wall St)
Present Value of 10-year Cash Flow (PVCF) = CN¥33b
We now need to calculate the Terminal Value, which accounts for all the future cash flows after this ten year period. The Gordon Growth formula is used to calculate Terminal Value at a future annual growth rate equal to the 5-year average of the 10-year government bond yield of 2.9%. We discount the terminal cash flows to today's value at a cost of equity of 7.4%.
Terminal Value (TV)= FCF2033 × (1 + g) ÷ (r – g) = CN¥5.8b× (1 + 2.9%) ÷ (7.4%– 2.9%) = CN¥132b
Present Value of Terminal Value (PVTV)= TV / (1 + r)10= CN¥132b÷ ( 1 + 7.4%)10= CN¥65b
The total value, or equity value, is then the sum of the present value of the future cash flows, which in this case is CN¥98b. The last step is to then divide the equity value by the number of shares outstanding. Compared to the current share price of CN¥31.1, the company appears quite undervalued at a 50% discount to where the stock price trades currently. The assumptions in any calculation have a big impact on the valuation, so it is better to view this as a rough estimate, not precise down to the last cent.
![dcf](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240627/0-7bec472c6f5834adb59d949df884fbaa-0-1ae6ce3b2dc337a8f4311255629169ae.png/big)
Important Assumptions
We would point out that the most important inputs to a discounted cash flow are the discount rate and of course the actual cash flows. Part of investing is coming up with your own evaluation of a company's future performance, so try the calculation yourself and check your own assumptions. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at Sichuan Kelun Pharmaceutical as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 7.4%, which is based on a levered beta of 0.800. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.
SWOT Analysis for Sichuan Kelun Pharmaceutical
- Earnings growth over the past year exceeded the industry.
- Debt is not viewed as a risk.
- Dividends are covered by earnings and cash flows.
- Dividend is in the top 25% of dividend payers in the market.
- Dividend information for 002422.
- Earnings growth over the past year is below its 5-year average.
- Shareholders have been diluted in the past year.
- Annual earnings are forecast to grow for the next 3 years.
- Good value based on P/E ratio and estimated fair value.
- Annual earnings are forecast to grow slower than the Chinese market.
- What else are analysts forecasting for 002422?
Next Steps:
Valuation is only one side of the coin in terms of building your investment thesis, and it shouldn't be the only metric you look at when researching a company. The DCF model is not a perfect stock valuation tool. Preferably you'd apply different cases and assumptions and see how they would impact the company's valuation. If a company grows at a different rate, or if its cost of equity or risk free rate changes sharply, the output can look very different. What is the reason for the share price sitting below the intrinsic value? For Sichuan Kelun Pharmaceutical, we've compiled three relevant aspects you should further examine:
- Risks: Take risks, for example - Sichuan Kelun Pharmaceutical has 2 warning signs we think you should be aware of.
- Future Earnings: How does 002422's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.
- Other Solid Businesses: Low debt, high returns on equity and good past performance are fundamental to a strong business. Why not explore our interactive list of stocks with solid business fundamentals to see if there are other companies you may not have considered!
PS. The Simply Wall St app conducts a discounted cash flow valuation for every stock on the SZSE every day. If you want to find the calculation for other stocks just search here.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com